SecBot SecBot
SECBOTREPLAY Home › Report › ARTV

ARTV · Artiva Biotherapeutics announced positive initial Phase 2a data for…

Artiva Biotherapeutics, Inc. · PRESS-RELEASE filed May 8, 2026 at 06:30 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed May 8, 2026 at 06:30 ET

Artiva Biotherapeutics announced positive initial Phase 2a data for AlloNK in refractory RA, showing 71% ACR50 at six months in its company-sponsored trial, and FDA alignment on a single registrational Phase 3 trial expected to start H2 2026. The data supports AlloNK's potential as an off-the-shelf deep B-cell depleting therapy with a favorable outpatient tolerability profile, de-risking the path to a BLA submission in 2029.

  • 71% ACR50 response at six months in company-sponsored Phase 2a basket trial (5 of 7 patients) in refractory RA.
  • FDA alignment on a single registrational Phase 3 trial for AlloNK in refractory RA, with ACR50 at six months as primary endpoint.
  • Phase 3 trial expected to enroll ~150 patients, randomized 2:1 AlloNK+rituximab vs rituximab alone, with crossover option.
  • No CRS, ICANS, or treatment discontinuations observed in autoimmune patients; tolerability supports outpatient community administration.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access